The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Booster Vaccination Against COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05077176
Recruitment Status : Completed
First Posted : October 14, 2021
Last Update Posted : February 29, 2024
Sponsor:
Information provided by (Responsible Party):
Health Institutes of Turkey

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a maximum of 270 days after the second dose of CoronaVac vaccine.

Condition or disease Intervention/treatment Phase
COVID-19 Sars-CoV-2 Infection Biological: CoronaVac Biological: Turkovac Phase 3

Detailed Description:

The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a maximum of 270 days after the second dose of CoronaVac vaccine. For the booster dose, subjects will be assigned open-label according to their preference for 2 different arms.

The booster dose vaccine arms are as follows:

  • CoronaVac
  • Turkovac
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4340 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination (CoronaVac or TURKOVAC) Against SARS-CoV-2
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2
Actual Study Start Date : October 8, 2021
Actual Primary Completion Date : May 10, 2023
Actual Study Completion Date : February 5, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: CoronaVac
Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
 Biological: CoronaVac
One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
Experimental: Turkovac
Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
 Biological: Turkovac
One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19 [ Time Frame: At least 14 days after booster vaccination dose ]
    Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19 confirmed by RT-PCR at least 14 days after booster vaccination dose.

  2. To Evaluate the SARS-CoV2 anti-spike protein immunoglobulin G [ Time Frame: 28 days after booster vaccination dose ]
    The change in the amount of SARS-CoV2 anti-spike protein immunoglobulin G in the 28th day compared to the baseline is 2 times or more

  3. Evaluation of SARS-CoV2 Neutralizing Antibodies [ Time Frame: 28 days after booster vaccination dose ]
    The change in the amount of SARS-CoV2 neutralizing antibodies in the 28th day compared to the baseline is 2 times or more

  4. T-Cell Evaluation [ Time Frame: 28 days after booster vaccination dose ]
    IL-2, TNF-alpha and IFN-gamma levels in T cells changed by 2 times or more on day 28 compared to baseline for 35 - 40 subjects


Secondary Outcome Measures :
  1. Incidence of Adverse Events (AE) [ Time Frame: On days 7 and 14 days after vaccination ]
    To evaluate the safety of booster dose vaccines by determining the incidence of adverse reactions.

  2. Incidence of Serious Adverse Events (SAE) [ Time Frame: 168 days after vaccination ]
    To evaluate the safety of booster dose vaccines by determining the incidence of serious adverse reactions.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study:

Inclusion Criteria:

  1. Subjects willing and able to give signed informed consent to participate in study,
  2. Healthy male or female aged 18 - 59 years (including both groups),
  3. Subjects who were vaccinated with CoronaVac for 2 doses and who had a minimum of 90 days and a maximum of 270 days after the second dose,
  4. Subjects with minimum 28 days and maximum 42 days between CoronaVac 1st and 2nd dose vaccines,
  5. Female subjects of childbearing potential should be willing to ensure that they or their partner use effective birth control methods continuously from 1 month before and up to 3 months after vaccination, Male subjects of potential to have children should be willing to ensure that they or their partner use effective birth control methods continuously from 1 month before and up to 3 months after vaccination,
  6. In the opinion of the investigator, subjects capable and willing to comply with all study requirements,
  7. Subjects are willing to agree to abstain from donating blood during the study.

Subjects meeting any of the following criteria will not be included in the study:

Exclusion Criteria:

  1. Administration of any vaccine (registered or investigational) other than study intervention within 30 days before and after each study vaccine (one week for authorized seasonal flu vaccine or pneumococcal vaccine),
  2. Pre-or planned use of another vaccine or product likely to affect the study (e.g. adenovirus vectored vaccines, any coronavirus vaccine),
  3. Known history of SARS-CoV-2 infection,
  4. Pregnant and puerperant subjects (subjects who become pregnant 2 months after vaccination will continue to study),
  5. Subjects with fever (above 37,8°C) at the time of vaccination and/or up to 72 hours before (After the acute condition has resolved, the subject can be screened again),
  6. Administration of immunoglobulins and/or any blood product within 3 months prior to vaccination,
  7. Any confirmed or suspected immunosuppressive or immunodeficiency state; asplenia; recurrent severe infections and use of immunosuppressants (less than ≤14 days) in the last 6 months, excluding topical steroids or short-term oral steroids,
  8. Possible history of allergic disease or reaction (e.g. to the active substance) by any component of the study vaccines,
  9. Any history of anaphylaxis,
  10. Current cancer diagnosis or treatment (excluding basal cell carcinoma of the skin and cervical carcinoma in situ),
  11. History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture,
  12. Continued use of anticoagulants such as coumarins and related anticoagulants (i.e. warfarin) or new oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban),
  13. Cerebral venous sinus thrombosis, antiphospholipid syndrome, or a history of heparin-induced thrombocytopenia and thrombosis (HITT or HIT type 2),
  14. Suspected or known current alcohol or drug addiction,
  15. Any other significant disease, disorder or finding that could significantly increase the subject's risk for participation in the study, affect the subject's ability to participate in the study, or impair the interpretation of study data; severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, kidney disease, endocrine disorder, and neurological disease (mild/moderate well-controlled comorbidities are permitted),
  16. History of active or previous autoimmune neurological disorders (e.g. multiple sclerosis, Guillain-Barre syndrome, transverse myelitis) (Bell's palsy will not be an exclusion criterion),
  17. Subjects with severe renal impairment or liver failure,
  18. Subjects who will undergo scheduled elective surgery during the study,
  19. Subjects with a life expectancy of less than 6 months,
  20. Subject who participated in another clinical trial study involving an investigational product in the past 12 weeks,
  21. In case of clinical necessity, a COVID-19 PCR (polymerase chain reaction) test will be requested from the subjects, and subjects who are positive will be excluded from the study,
  22. Acute respiratory disease (moderate or severe illness with or without fever). (Subjects may be screened again after acute condition has resolved),
  23. Insufficient level of Turkish to perform the informed consent, except where briefing by an independent witness can be provided and is available.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05077176


Locations
Show Show 41 study locations
Sponsors and Collaborators
Health Institutes of Turkey
Investigators
Layout table for investigator information
Principal Investigator: Bedia Dinç, Assoc. Prof. Faculty Member
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Health Institutes of Turkey
ClinicalTrials.gov Identifier: NCT05077176    
Other Study ID Numbers: Inaktif_Rapel_Faz 3
First Posted: October 14, 2021    Key Record Dates
Last Update Posted: February 29, 2024
Last Verified: February 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Health Institutes of Turkey:
COVID-19
SARS-CoV-2 Vaccine
Booster
 Efficacy
Immunogenicity
Safety
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases